The use of powerful synthetic opioids, such as sufentanil and remifentanil, during surgery is linked to a subsequent poor ...
Enveric Biosciences secures a U.S. patent for non-hallucinogenic mescaline derivatives targeting addiction, ADHD and anxiety.
The one-size-fits-all approach to pain management should be a thing of the past. But we’re still not there yet.
Researchers from McMaster University and collaborating institutions found that commonly performed interventional procedures ...
Advancements have been made in the pain management field that have successfully found FDA approved alternatives to ...
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...
The Horry County Coroner's Office announced Friday that it is monitoring the rise in overdose deaths involving Xylazin.Xylazin is a non-opioid veterinary sedati ...
On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...
One of the scariest moments of my life happened in 2022 when my father, Tom Donvito, then 75 and unaware of any allergies, experienced an anaphylactic reaction to a hornet sting. After he passed ...
The US FDA has approved Journavx, a new pain reliever without the risks for addiction or overdose linked to drugs like Vicodin and OxyContin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback